CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria Vaccine

Infection and Immunity

Volumn 72, Issue 2, 2004, Pages 949-957

  Kumar, Sanjai ^a,b,f   Jones, Trevor R ^a   Oakley, Miranda S ^a   Zheng, Hong ^a   Kuppusamy, Shanmuga P ^a   Taye, Alem ^a   Krieg, Arthur M ^c,d   Stowers, Anthony W ^e,g   Kaslow, David C ^e,h   Hoffman, Stephen L ^a,i  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^g CSL LIMITED   (Australia)

^h VICAL INC   (United States)

ⁱ SANARIA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MONTANIDE ISA 51; OLIGODEOXYNUCLEOTIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PARASITE; PLASMODIUM YOELII; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-12; MALARIA VACCINES; MANNITOL; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED C57BL; OLEIC ACIDS; OLIGODEOXYRIBONUCLEOTIDES; PLASMODIUM YOELII; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 10744224734     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.2.949-957.2004     Document Type: Article

References (46)

1. Blackman, M. J., H. G. Heidrich, S. Donachie, J. S. McBride, and A. A. Holder. 1990. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J. Exp. Med. 172:379-382.
2. Blackman, M. J., I. T. Ling, S. C. Nicholls, and A. A. Holder. 1991. Proteolytic processing of Plasmodium falciparum merozite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol. Biochem. Parasitol. 49:29-33.
3. Bohle, B. 2002. CpG motifs as possible adjuvants for the treatment of allegic diseases. Int. Arch. Allergy Immunol. 129:198-203.
4. Carpentier, A. F., G. Auf, and J. Y. Delattre. 2003. CpG-oligonucleotides for cancer immunotherapy: Review of the literature and potential applications in malignant glioma. Front. Biosci. 8:115-127.
5. Carr, A., E. Rodriguez, M. C. Arango, R. Camacho, M. Osorio, M. Gabri, G. Carrillo, Z. Valdes, Y. Bebelagua, R. Perez, and L. E. Fernandez. 2003. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J. Clin. Oncol. 21:1015-1021.
6. Chang, S. P., S. E. Case, W. L. Gosnell, A. Hashimoto, K. J. Kramer, L. Q. Tam, C. Q. Hahiro, C. M. Nikaido, H. L. Gibson, C. T. Lee-Ng, P. J. Barr, B. T. Yokata, and G. S. N. Hui. 1987. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein-1 protects Aotus monkeys against malaria. Infect. Immun. 64:253-261.
7. Chang, S. P., H. L. Gibson, C. T. Lee-Ng, P. J. Barr, and G. S. N. Hui. 1992. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J. Immunol. 149:548-555.
8. Chang, S. P., S. E. Case, W. L. Gosnell, A. Hashimoto, K. J. Kramer, L. Q. Tam, C. Q. Hashiro, C. M. Nikaido, H. L. Gibson, C. T. Lee-Ng, P. J. Barr, B. T. Yokota, and G. S. Hui. 1996. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect. Immun. 64:253-261.
9. Cherwinski, H. M., J. H. Schumacher, K. D. Brown, and T. R. Mosmann. 1987. Two types of mouse helper T-cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J. Exp. Med. 166:1229-1244.
10. Cowdery, J. S., J. H. Chace, A. K. Yi, and A. M. Krieg. 1996. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:4570-4575.
11. Daly, T. M., and C. A. Long. 1993. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii 17XL merozoite surface protein-1 induces a protective immune response in mice. Infect. Immun. 61: 2462-2467.
12. Daly, T. M., and C. Long. 1995. Humorai immune response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood stage infection in rodent malaria. J. Immunol. 155:236-243.
13. Davis, H. L., R. Weeranta, T. J. Waldschmidt, L. Tygrett, J. Schorr, and A. M. Krieg. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870-876.
14. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M. Pierres, and F. W. Fitch. 1983. Characterization of the murine T-cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131:2445-2451.
15. + T cells in the Plasmodium yoelii model. J. Immunol. 163:884-892.
16. Doolan, D. L., and S. L. Hoffman. 2002. Nucleic acid vaccines against malaria. Chem. Immunol. 80, p. 308-320. In P. Perlman and M. Troye-Bloomberg (ed.). Malaria Immunology. Karger, Basel, Switzerland, Germany.
17. Gardner, M. J., N. Hall, E. Fung, O. White, M. Berriman, R. W. Hyman, J. M. Carlton, A. Pain, K. E. Nelson, S. Bowman, I. T. Paulsen, K. James, J. A. Eisen, K. Rutherford, S. L. Salzberg, A. Craig, S. Kyes, M. S. Chan, V. Nene, S. J. Shallom, B. Suh, J. Peterson, S. Angiuoli, M. Pertea, J. Allen, J. Selengut, D. Haft, M. W. Mather, A. B. Vaidya, D. M. Martin, A. H. Fairlamb, M. J. Fraunholz, D. S. Roos, S. A. Ralph, G. I. McFadden, L. M. Cummings, G. M. Subramanian, C. Mungall, J. C. Venter, D. J. Carucci, S. L. Hoffman, C. Newbold, R. W. Davis, C. M. Fraser, and B. Barrell. 2002. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419:498-511.
18. Genton, B., I. Betuela, I. Felger, F. Al-Yaman, R. F. Anders, A. Saul, L. Rare, M. Baisor, K. Lorry, G. V. Brown, D. Pye, D. O. Irving, T. A. Smith, H. P. Beck, and M. P. Alpers. 2002. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on populations in a phase 1-2b trials in Papua New Guinea. J. Infect. Dis. 185:820-827.
19. Gramzinski, R. A., D. L. Doolan, M. Sedegah, H. L. Davis, A. M. Krieg, and S. L. Hoffman. 2001. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligonucleotide in mice. Infect. Immun. 69:1643-1649.
20. Gursel, M., D. Verthelyi, and D. M. Klinman. 2002. CpG oligonucleotides induce human monocytes to mature into functional dendritic cells. Eur. J. Immunol. 32:2617-2622.
21. 19) of Plasmodium yoelii expressed in Saccharomyces cerevisiae. J. Immunol. 159:3400-3411.
22. Jones, T. R., D. L. Narum, A. S. Gozalo, J. Aguiar, S. R. Fuhramann, S. R., H. Liang, J. D. Haynes, J. K. Moch, C. Lucas, T. Luu, A. J. Magill, and S. L. Hoffman. 2000. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J. Infect. Dis. 183:303-312.
23. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12, and IFN-γ. Proc. Natl. Acad. Sci. 93:2879-2883.
24. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. Koretzky, and D. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
25. Krieg, A. M. 2003. CpG motifs: the active ingredient in bacterial extracts. Nat. Med. 9:831-835.
26. Kumar, S., A. Yadava, D. B. Keister, J. H. Tian, M. Ohl, K. A. Perdue-Greenfield, L. H. Miller, and D. C. Kaslow. 1995. Immunogenicity and in vivo efficacy of recombinant Plasmodiam falciparum merozite surface protein-1 in Aotus monkeys. Mol. Med. 1:325-332.
27. Kumar, S., D. C. Kaslow, and S. L. Hoffman. 1999. An overview of malaria vaccine development efforts, p. 397-442. In P. Perlman, H. Wigzell (ed.), Vaccines. Handbook of experimental pharmacology. Springer, Berlin, Germany.
28. Kumar, S., W. Collins, A. Egan, A. Yadava, O. Garraud, M. J. Blackman, J. A. Guevara Patino, C. Diggs, and D. C. Kaslow. 2000. Immunogenicity and efficacy in Aotas monkeys of four recombinant Plasmodiam falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect. Immun. 68:2215-2223.
29. Kumar, S., J. E. Epstein, and T. L. Richie. 2002. Vaccines against asexual stage malaria parasites, p. 262-279. In P. Perlman and M. T. Troye-Blomberg (ed.), Malaria immunology. Karger, Basel, Switzerland, Germany.
30. Kumar, S., F. Villinger, M. Oakley, J. C. Aguiar, T. R. Jones, R. C. Hedstrom, K. Gowda, J. Chute, A. Stowers, D. C. Kaslow, E. K. Thomas, J. Tine, D. Klinman, S. L. Hoffman, and W. W. Weiss. 2002. A DNA vaccine encoding the 42 kDa C terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T-cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor. Immunol. Lett. 81:13-24.
31. Langhorne, J., S. J. Quin, and L. A. Sanni. 2002. Mouse models of blood stage malaria infections: Immune responses and cytokines involved in protection and pathology, p. 204-221. In P. Perlman and M. T. Troye-Blomberg (ed.), Malaria immunology. Karger, Basel, Switzerland.
32. Ling I. T., S. A. Ogun, and A. A. Holder. 1994. Immunization against malaria with a recombinant protein. Parasite Immunol. 16:63-67.
33. Near, K. A., A. W. Stowers, D. Jankovic, and D. C. Kaslow. 2002. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect. Immun. 70:692-701.
34. Sachs, J. D. 2002. A new effort to control malaria. Science 298:122-123.
35. Sarmiento, M., A. L. Glasebrook, and F. W. Fitch. 1980. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T-cell-mediated cytolysis in the absence of complement. J. Immunol. 125:2665-2672.
36. + T cells, and antibodies required for immunity to malaria sporozoites. Nature 330:664-666.
37. Siddiqui, W. A., L. Q. Tam, K. J. Kramer, G. S. Hui, S. E. Case, K. M. Yamaga, S. P. Chang, E. B. Chan, and S. C. Kan. 1987. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. 84:3014-3018.
38. Stoute, J. A., K. E. Kester, U. Krzych, B. T. Wellde, T. Hall, K. White, G. Glenn, C. F. Ockenhouse, N. Garcon, R. Schwenk, D. E. Lanar, P. Sun, P. Momin, R. A. Wirtz, C. Golenda, M. Slaoui, G. Wortmann, C. Holland, M. Dowler, J. Cohen, and W. R. Ballou. 1998. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine. J. Infect. Dis. 178:1139-1144.
39. Stowers, A. H., L. H. Chen, Y. Zhang, M. C. Kennedy, L. Zou, L. Lambert, T. J. Rice, D. C. Kaslow, A. Saul, C. A. Long, H. Meade, and L. H. Miller. 2002. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc. Natl. Acad. Sci. 99:339-344.
40. Tian, J. H., L. H. Miller, D. C. Kaslow, J. Ahlers, M. F. Good, D. W. Alling, J. A. Berzofsky, and S. Kumar. 1996. Genetic regulation of protective immune responses in congenic strains of mice vaccinated with a subunit malaria vaccine. J. Immunol. 157:1176-1181.
41. Tian, J. H., S. Kumar, D. C. Kaslow, and L. H. Miller. 1997. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii. Infect. Immun. 65:3032-3036.
42. Uhlmann, E., and J. Vollmer. 2003. Recent advances in the development of immunostimulatory oligonucelotides. Curr. Opin. Drug Discov. Dev. 6:204-217.
43. Verthelyi, D., M. Gursel, R. T. Kenney, J. D. Lifson, S. Liu, J. Mican, and D. M. Klinman. 2003. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol. 170:4717-4723.
44. World Health Organization. 1998. Fact Sheet 94. World Health Organization, Geneva, Switzerland.
45. World Health Organization. 2001. Commission on Macroeconomics and Health: investing in health for economic development Geneva, Switzerland.
46. Wysocka, M., M. Kubin, L. Q. Vieira, L. Ozmen, G. Garotta, P. Scott, and G. Trincheri. 1995. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25: 672-676.